Technical Considerations in the choice and use of ctDNA for Large B-cell lymphoma (LBCL)

Diffuse Large B-cell lymphoma is an aggressive lymphoma in which management is constrained by incomplete molecular characterization and the absence of sensitive markers of treatment response. Cell-free DNA offers a noninvasive approach for tumor genotyping and minimal residual disease monitoring. Nevertheless, technical challenges persist, including low cfDNA abundance and the discrimination of low allele fraction variants from background noise. Tumor-informed assays tracking multiple genetic markers substantially improve sensitivity of disease monitoring. Standardization and prospective validation will facilitate routine clinical implementation.